Buscar
Longeveron Inc
LGVNAñadir a la lista de seguimiento
0.670USD
-0.032-4.57%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
20.88MCap. mercado
PérdidaP/E TTM
Más Datos de Longeveron Inc Compañía
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Información de Longeveron Inc
Símbolo de cotizaciónLGVN
Nombre de la empresaLongeveron Inc
Fecha de salida a bolsaFeb 12, 2021
Director ejecutivoPowell (Than)
Número de empleados25
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 12
Dirección1951 NW 7th Ave
CiudadMIAMI
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33136
Teléfono13053027158
Sitio Webhttps://www.longeveron.com/
Símbolo de cotizaciónLGVN
Fecha de salida a bolsaFeb 12, 2021
Director ejecutivoPowell (Than)
Ejecutivos de Longeveron Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
355.14K
+70.39%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
342.88K
+72.91%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
302.11K
+82.75%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
251.15K
-0.77%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
24.92K
-42.67%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+76.12%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
13.58K
-54.61%
Mr. Rock Soffer
Mr. Rock Soffer
Director
Director
--
--
Mr. Paul Lehr, J.D.
Mr. Paul Lehr, J.D.
General Counsel and Secretary
General Counsel and Secretary
--
--
Mr. Than Powell
Mr. Than Powell
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
355.14K
+70.39%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
342.88K
+72.91%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
302.11K
+82.75%
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
251.15K
-0.77%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
24.92K
-42.67%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+76.12%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Por negocioUSD
Nombre
Ganancia
Proporción
Clinical trial revenue
954.00K
79.57%
Contract manufacturing
222.00K
18.52%
Contract manufacturing lease revenue
23.00K
1.92%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Clinical trial revenue
954.00K
79.57%
Contract manufacturing
222.00K
18.52%
Contract manufacturing lease revenue
23.00K
1.92%
Estadísticas de accionistas
Actualizado: jue., 14 de may
Actualizado: jue., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Willard (Stephen H)
2.84%
Armistice Capital LLC
2.43%
Vanguard Capital Management, LLC
1.95%
Lehr (Paul T)
1.77%
Locklear (Lisa)
1.28%
Otro
89.73%
Accionistas
Accionistas
Proporción
Willard (Stephen H)
2.84%
Armistice Capital LLC
2.43%
Vanguard Capital Management, LLC
1.95%
Lehr (Paul T)
1.77%
Locklear (Lisa)
1.28%
Otro
89.73%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
11.21%
Investment Advisor
2.72%
Hedge Fund
2.55%
Investment Advisor/Hedge Fund
0.89%
Venture Capital
0.11%
Research Firm
0.02%
Otro
82.51%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
62
2.25M
8.08%
+1.13M
2025Q4
59
1.71M
8.62%
+623.94K
2025Q3
58
1.73M
8.71%
+931.02K
2025Q2
73
2.18M
16.11%
+296.38K
2025Q1
73
2.14M
15.82%
-119.71K
2024Q4
73
2.53M
18.80%
+652.31K
2024Q3
67
2.33M
17.58%
+1.38M
2024Q2
67
924.88K
16.16%
+194.99K
2024Q1
64
168.05K
15.95%
-258.83K
2023Q4
68
363.47K
37.19%
+110.22K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Willard (Stephen H)
294.47K
1.06%
+294.47K
--
Mar 02, 2026
Armistice Capital LLC
676.23K
2.43%
+676.23K
--
Sep 30, 2024
Lehr (Paul T)
318.40K
1.15%
-6.95K
-2.14%
Jan 02, 2026
Locklear (Lisa)
142.17K
0.51%
-10.25K
-6.73%
Jan 02, 2026
Agafonova (Nataliya)
129.90K
0.47%
-10.25K
-7.31%
Jan 02, 2026
Blass (Devin)
91.84K
0.33%
-10.70K
-10.43%
Jan 02, 2026
Hare (Joshua M)
253.07K
0.91%
-5.25K
-2.03%
May 16, 2025
Hashad (Mohamed Wa'el Ahmed)
310.90K
1.12%
+166.85K
+115.83%
Jul 15, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
